錠剤/カプセル/ソフトジェルの外観検査の世界市場（2025年～2032年）

世界の錠剤/カプセル/ソフトジェルの外観検査の市場規模は、2024年に5億8,626万米ドルに達し、2032年には8億9,772万米ドルに達すると予測され、予測期間2024年～2032年のCAGRは5.5%で成長する見通しです。

錠剤やカプセルのような経口固形製剤を扱う医薬品・ヘルスケア製品メーカーは、製品の安全性を保証するために確実な品質検査を必要としています。製品を市場に投入する前に、品質モニタリングは極めて重要です。医薬品向けの錠剤/カプセル/ソフトジェルを扱う場合、その重要性はさらに高まります。錠剤検査機はこのような場面で役立ちます。ベルトコンベアを使って、錠剤やカプセルを順番に徹底的に検査する機械です。これは、消費者が購入できるのは高品質の製品だけであることを保証する、迅速かつ効果的なプロセスです。外観検査機の高速カメラとカスタマイズされたソフトウェアは、錠剤の色、形、サイズの不一致を正確に検出し、特注の不良品排除メカニズムによって不良品を取り除くことができます。システムは、個々の製品やボトルを拒否するように設定することができます。

市場力学：

促進要因と抑制要因

医薬品生産量の増加

慢性疾患の世界の負担増による需要拡大により、世界的に医薬品の生産量は近年大幅に増加しています。医薬品メーカーの大半は、消費者の需要を満たすために生産量を拡大しています。医薬品製造の市場リーダーとして、いくつかの国が立ち上がりつつあります。例えば、インド政府の報道情報局は、インドは絶え間ない投資と需要の高まりに後押しされ、医薬品事業で飛躍的な成長を遂げていると述べています。同国の医薬品産業は、主要な市場促進要因としての国内製造の増加により、2025年までに1,000億米ドルに達すると予想されています。また、同国の輸出量は2023年～2024年に8.36％増加しています。これは、同国が医薬品分野を重視し、生産量の向上に注力していることを反映しています。同様のシナリオは、中国、ブラジル、東欧諸国、東南アジア諸国といった他の新興国でも続いています。

医薬品生産量の増加に伴い、外観検査システムの需要は今後大幅に増加すると予想されます。このことは、予測期間中の市場成長をプラスに推進すると思われます。

人工知能の普及が市場成長を促進

新時代の技術の中でも、人工知能（AI）は医薬品製造において急成長している技術です。初期段階の医薬品開発から最終段階の商業生産まで、重要な役割を果たしています。医薬品の外観検査において、この技術は錠剤/カプセル/ソフトジェルを高精度で迅速に分析し、検査時間全体を短縮することができます。例えば、ACGとProditecのVISITABシリーズの画像検査システムは、AI技術と統合されており、医薬品の微細な製造不良も検出できるように設計されています。

AIシステムはまた、組立ライン上の製品の品質が悪い場合、適切な変更を行うよう品質担当者に警告を発します。また、システムのトレーニングには人間の関与はほとんど必要なく、機械は自分自身から新しい動作を学習し続け、その効率を段階的に向上させます。

AIを活用した外観検査工程は、人間の品質検査員をいつでも凌駕することができます。この新時代のソリューションは、欠陥や不具合をより早期に特定するよう訓練することができます。スマートカメラとセンサーは、生産ラインのエンド・ツー・エンドの可視性を確保し、AIベースのソリューションを訓練するために不可欠なデータと画像をキャプチャします。

AIを搭載したシステムは、卓越した精度で欠陥を検出・特定する優れた能力を持ち、一貫性と客観性を維持する上で人間の検査員のスキルを補完します。AIは、検査員がより効率的に業務を遂行し、より多くの情報に基づいた意思決定を行うことを可能にする、貴重な補助となります。

外観検査にAIを統合する主な利点の1つは、人間の視覚からは見えない危険な領域での複雑な検査を処理する能力にあります。カメラ技術とコンピューター・ビジョン・アルゴリズムの継続的な進歩により、メンテナンス技術者は検査対象物から安全な距離を保ちながら遠隔で検査を行うことができます。この画期的な技術により、作業員の安全性と設備の完全性が確保され、リスクが軽減され、ダウンタイムが最小限に抑えられます。

スケーラビリティは、手作業と比較したAIの検査のもう一つの利点です。経験豊富な検査員の専門知識と熟練度に匹敵するよう、別の人間の検査員を訓練するには、時間とリソース、多額の投資が必要です。一方、AI検査システムの拡張には、ソフトウェアを複製して検査ステーションを増設したり、既存のインフラに統合したりする必要があります。この拡張性により、企業は人間に大きく依存することなく、スループットを向上させ、より大量の検査を処理することができます。

これは生産における品質保証であり、高品質の最終出力で組立ライン上の製品に望ましいレベルの品質と標準を維持することを目的としています。コンピュータ・ビジョンはAIのサブセットであり、人間の目が行う機能と非常によく似たデジタル視覚データを理解するアルゴリズムを使用します。

手作業による従来の外観検査アプローチは、時間がかかるだけでなく、それぞれの品質検査担当者の主観的な認識や経験によってエラーが発生しやすくなっています。これは、品質管理プロセスの一貫性に影響を与え、特定の時間内に検出される欠陥の数が限られてしまう原因となります。さらに、レガシーシステムは柔軟性に欠け、製品の変更に対応するために頻繁に再設定しなければなりません。また、時間と労力がかかります。

外観検査システムの高コストが市場成長を抑制する可能性

外観検査システムの技術的進歩は著しいですが、機能の追加には追加価格がかかる可能性があります。 AIのような新時代の技術と統合された自動外観検査システムのコストは、手動システムや半自動システムよりも大幅に高くなる可能性があります。初期投資コストが高いため、中低価格帯の製造企業は、従来の手作業による検査に頼っている可能性があります。このような企業では、新しい技術を搭載したシステムの採用率が大幅に低下する可能性があり、市場成長の妨げとなっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 医薬品生産量の増加
    • 検査技術の進歩
  • 抑制要因
    • 高度な外観検査機器の高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 価格分析
• 特許分析
• 規制分析

第6章 運用方法別

• 自動
• 半自動
• マニュアル

第7章 用途別

• 錠剤
• カプセル
• ソフトジェル

第8章 エンドユーザー別

• 製薬業界
• 栄養補助食品業界
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Daiichi Jitsugyo Asia Pte. Ltd.
  • 会社概要
  • 製品ポートフォリオ
  • 財務概要
  • 主な発展
  • SWOT分析
• Accura Pharmaquip Pvt. Ltd.
• Proditec
• Jekson Vision
• SaintyCo
• METTLER TOLEDO.
• Anritsu
• Sensum d.o.o.
• YENCHEN MACHINERY CO., LTD.
• Key International 2025, Inc.
• MELISCOUT GMBH

第12章 付録

The global visual inspection of tablets, capsules, and softgels market reached US$ 586.26 million in 2024 and is expected to reach US$ 897.72 million by 2032, growing at a CAGR of 5.5% during the forecast period 2024-2032.

Pharmaceuticals and healthcare product manufacturers dealing with oral solid products such as tablets and capsules need a fool-proof quality inspection to assure product safety. Before putting a product on the market, quality monitoring is crucial. When it comes to dealing with tablets, capsules, and softgels intended for the pharmaceutical business, this is of more importance. A tablet inspection machine can be useful in this situation. These machines use a conveyor belt to thoroughly examine each tablet or capsule in turn. This is a quick and effective process that guarantees that only high-quality products are available for consumers to purchase. The high-speed cameras and customized software of the visual inspection machines are capable of accurately detecting inconsistencies in tablet color, shape, and size, removing defective products via a custom-built rejection mechanism. The system can be configured to reject individual products or bottles.

Market Dynamics: Drivers & Restraints

Rising pharmaceutical production volumes

Globally the production of pharmaceuticals has significantly risen in recent times due to increasing demand caused by the escalating global burden of chronic diseases. Majority of the pharmaceutical manufacturers are scaling up their production volumes to meet consumer demands. Several nations are stepping up to stand as market leaders in pharmaceutical production. For instance, the Press Information Bureau of the Government of India has stated that India has been drastically growing in the pharmaceutical business fueled by constant investments and higher demand. The country's pharmaceutical industry is expected to reach US$ 100 billion by 2025 with the rising domestic manufacturing as a major market driver. The country's export volume has also increased by 8.36% from 2023 to 2024. This reflects the country's growing emphasis on the pharmaceutical sector and its focus on improving production volume. A similar scenario is continued in other emerging nations such as China, Brazil, Eastern European countries, and Southeast Asian countries.

With the growing pharmaceutical product volumes, the requirement for visual inspection systems is expected to significantly rise in the future. This will propel the market growth positively in the forecast period.

The rising adoption of artificial intelligence fuels market growth

Among all the new-age technologies, Artificial Intelligence (AI) is fast fast-growing technology in pharmaceutical manufacturing. It plays a crucial role in early-stage drug development to end-stage commercial manufacturing. In the pharmaceutical's visual inspection, this technology can rapidly analyze tablets, capsules, and softgels with high precision and reduce the overall inspection time. For instance, the VISITAB series of vision inspection systems by ACG and Proditec are integrated with AI technologies are designed to detect even a minute manufacturing defects in pharmaceutical products.

The AI systems also alert the quality personnel to make relevant changes when the quality of the product on the assembly line is poor. Also, training the system requires almost zero human involvement, and the machine keeps learning new behaviors from itself to improve its efficiencies incrementally.

AI-powered visual inspection processes can outperform human quality inspectors any day. This new-age solution can be trained to identify defects and failures much earlier. Smart cameras and sensors ensure end-to-end visibility of the production line and capture data and images which are crucial to train the AI-based solution.

AI-powered systems possess the remarkable ability to detect and identify defects with exceptional precision, complementing the skills of human inspectors in maintaining consistency and objectivity. AI is a valuable supplement, enabling inspectors to perform their tasks more effectively and make more informed decisions.

One of the key advantages of integrating AI into visual inspection lies in its ability to handle complex inspections in hazardous areas that are hidden from human vision. With the continuous advancements in camera technology and computer vision algorithms, maintenance technicians can conduct inspections remotely while maintaining a safe distance from the objects under examination. This breakthrough ensures both the safety of personnel and the preservation of equipment integrity, mitigating risks and minimizing downtime.

Scalability is another advantage of AI inspection compared to manual methods. Training another human inspector to match the expertise and proficiency of an experienced inspector takes time, resources, and considerable investment. On the other hand, scaling AI inspection systems involves replicating software and deploying it to additional inspection stations or integrating it into existing infrastructure. This scalability allows businesses to increase throughput and handle higher volumes of inspections without the need for significant reliance on humans.

It is quality assurance in production that aims to preserve a desired level of quality and standard in a product on the assembly line with a high-quality final output. Computer vision, an AI subset uses algorithms to understand digital visual data very similar to the function performed by the human eye.

Manual traditional visual inspection approaches are not only time-consuming but are prone to errors due to the subjective perception and experience of the respective quality inspector. This impacts consistency in the quality control process where only a limited number of defects are detected within a given time. Furthermore, legacy systems are not flexible and have to be reconfigured frequently to accommodate product changes. It is also time-consuming and labor-intensive.

The high cost of visual inspection systems may restrain the market growth.

The technological advancements are growing in the visual inspection systems, however, additional features may come at additional prices. The cost of automated visual inspection systems integrated with new-age technologies like AI, can be significantly higher than manual systems, or semi-automated systems. Due to the high initial investment cost, low to mid-range manufacturing companies may rely on the traditional practice of manual inspection. The adoption rate for a novel, tech-loaded systems can significantly reduce among these manufacturers hindering their market growth.

Segment Analysis

The global visual inspection of tablets, capsules, and softgels market is segmented based on mode of operation, application, end-user, and region.

Automatic systems in the mode of operation segment are expected to grow with the highest CAGR in the forecast period.

An automatic visual inspection machine for tablets and capsules has a digital image recognition technology that can assist in the precise detection of physical damage on tablets and capsules. These devices find their major application in medium to large-scale manufacturing facilities due to their high efficiency. The automatic visual inspection machines are specifically used to inspect size mismatches, breakage, the presence of foreign objects, and twining on tablets and capsules. There are several automated visual inspection systems with advanced features.

For instance, SPINE by Sensum d.o.o. is an all-in-one automated machine for 100% visual inspection and sorting of tablets, capsules, and softgels. The device can inspect 830 products per hour and can visualize products between 2mm to 28mm in size. Various types of tablets can be inspected, such as coated or uncoated, multilayer, laser-drilled, or those with engraving. The machine can inspect full or empty capsules, as well as those with print or that are transparent.

Automatic machines deliver the seamless inspection of quality through the system setting and apply the best algorithm as well without structural change or complicated settings. Automatic visual inspection machines are also designed with technological advancements like AI technologies to enhance advanced features and high visuality with 2D and 3D inspection.

All these features of automatic machines reflect their potential for widespread adoption in the future.

Geographical Analysis

North America dominates the visual inspection of tablets, capsules, and softgels market.

North America is renowned for its pharmaceutical industry. Manufacturers in the U.S. have adopted advanced technologies and machines for pharmaceutical production and inspection. Moreover, the market players in visual inspection machines have a strong presence in the U.S., and they offer visual inspection machines integrated with advanced technologies such as AI. For instance, Key International Inc., a company based in New Jersey, U.S., and one of the global market leaders offers its highly advanced Enclony PLANET 6G inspection machine to manufacturers in the United States. The machine takes up to 12 pictures of every tablet or capsule that passes through it. The machine also compares each tablet or capsule against a "golden image" to assure 100% visual inspection, keeping the good product and rejecting any defective product. With its combined state-of-the-art features, the Enclony PLANET 6G is capable of inspecting any shape, size, or color tablet or capsule. It also boasts 350,000 tablets per hour or 150,000 capsules per hour output to streamline efficiency.

Competitive Landscape

The major global players in the visual inspection of tablets, capsules, and softgels market are Daiichi Jitsugyo Asia Pte. Ltd., Accura Pharmaquip Pvt. Ltd., Proditec, Jekson Vision, SaintyCo, METTLER TOLEDO., Anritsu, Sensum d.o.o., YENCHEN MACHINERY CO., LTD. Key International 2025, Inc. and MELISCOUT GMBH among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing product and technology developments, and forecasts upcoming advancements.
• Target Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates customer feedback and data into product development for improved outcomes.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Target delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global interleukin inhibitors market report would provide approximately 86 tables, 69 figures, and 265 pages.

Target Audience 2024

• Manufacturers: Technology Innovators, Product Manufacturers, Contract Manufacturers, Distributors.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Mode of Operation
• 3.2. Snippet by Application
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising pharmaceutical production volumes
    • 4.1.1.2. Advancements in inspection technologies
  • 4.1.2. Restraints
    • 4.1.2.1. High cost of advanced visual inspection machines
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Pricing Analysis
• 5.3. Patent Analysis
• 5.4. Regulatory Analysis

6. By Mode of Operation

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Operation
  • 6.1.2. Market Attractiveness Index, By Mode of Operation
• 6.2. Automatic*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Semi-Automatic
• 6.4. Manual

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Tablets*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Capsules
• 7.4. Softgels

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Pharmaceutical Industry*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Nutraceutical Industry
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

• 11.1. Daiichi Jitsugyo Asia Pte. Ltd.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
  • 11.1.5. SWOT Analysis
• 11.2. Accura Pharmaquip Pvt. Ltd.
• 11.3. Proditec
• 11.4. Jekson Vision
• 11.5. SaintyCo
• 11.6. METTLER TOLEDO.
• 11.7. Anritsu
• 11.8. Sensum d.o.o.
• 11.9. YENCHEN MACHINERY CO., LTD.
• 11.10. Key International 2025, Inc.
• 11.11. MELISCOUT GMBH
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us